In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Doripenem, a 1beta-methylcarbapenem, is a broad-spectrum antibiotic approved for the treatment of complicated urinary tract and complicated intra-abdominal infections. An indication for hospital-acquired pneumonia including ventilator-associated pneumonia is pending. The current study examined the activity of doripenem against recent clinical isolates for the purposes of its ongoing clinical development and future longitudinal analysis. Doripenem and comparators were tested against 12,581 U.S. clinical isolates collected between 2005 and 2006 including isolates of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pneumoniae, Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. MICs (microg/ml) were established by broth microdilution. By MIC(90), doripenem was comparable to imipenem and meropenem in activity against S. aureus (methicillin susceptible, 0.06; resistant, 8) and S. pneumoniae (penicillin susceptible, < or =0.015; resistant, 1). Against ceftazidime-susceptible Enterobacteriaceae, the MIC(90) of doripenem (0.12) was comparable to that of meropenem (0.12) and superior to that of imipenem (2), though susceptibility of isolates exceeded 99% for all evaluated carbapenems. The activity of doripenem was not notably altered against ceftazidime-nonsusceptible or extended-spectrum beta-lactamase screen-positive Enterobacteriaceae. Doripenem was the most potent carbapenem tested against P. aeruginosa (MIC(90)/% susceptibility [%S]: ceftazidime susceptible = 2/92%S, nonsusceptible = 16/61%S; imipenem susceptible = 1/98.5%S, nonsusceptible = 8/56%S). Against imipenem-susceptible Acinetobacter spp., doripenem (MIC(90) = 2, 89.1%S) was twice as active by MIC(90) as were imipenem and meropenem. Overall, doripenem potency was comparable to those of meropenem and imipenem against gram-positive cocci and doripenem was equal or superior in activity to meropenem and imipenem against Enterobacteriaceae, including beta-lactam-nonsusceptible isolates. Doripenem was the most active carbapenem tested against P. aeruginosa regardless of beta-lactam resistance.
Pillar
Chris M
CM
Eurofins Medinet, Inc., Anti-Infectives Services, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA. Chris.Pillar@eurofinsmedinet.com
Torres
Mohana K
MK
Brown
Nina P
NP
Shah
Dineshchandra
D
Sahm
Daniel F
DF
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D000077726:Doripenem; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006095:Gram-Positive Cocci / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards*; D014481:United States
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:59-64
11420337
Clin Microbiol Infect. 2002 Jun;8(6):321-31
12084099
Curr Opin Microbiol. 2005 Oct;8(5):518-24
16126451
Antimicrob Agents Chemother. 2004 Apr;48(4):1313-9
15047535
Antimicrob Agents Chemother. 1998 Jan;42(1):94-9
9449267
Diagn Microbiol Infect Dis. 2005 May;52(1):71-4
15878447
Chemotherapy. 2000 May-Jun;46(3):184-7
10765033
J Antibiot (Tokyo). 1996 Feb;49(2):199-209
8621362
J Antimicrob Chemother. 2007 Jul;60(1):78-82
17490999
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96
15047550
Antimicrob Agents Chemother. 2004 Aug;48(8):3136-40
15273134
Diagn Microbiol Infect Dis. 2006 Jul;55(3):241-3
16725297
Am J Infect Control. 2006 Jun;34(5 Suppl 1):S20-8; discussion S64-73
16813978
J Antimicrob Chemother. 2006 Aug;58(2):320-6
16735428
Biochem Pharmacol. 2006 Mar 30;71(7):1085-95
16413506
N Engl J Med. 2005 Jan 27;352(4):380-91
15673804
Clin Microbiol Infect. 2001 Nov;7(11):597-608
11737084
Clin Infect Dis. 2002 Mar 1;34(5):634-40
11823954
Antimicrob Agents Chemother. 2004 Aug;48(8):3086-92
15273124
Clin Microbiol Infect. 2006 Sep;12(9):826-36
16882287
J Antimicrob Chemother. 2000 Sep;46(3):471-4
10980177
Antimicrob Agents Chemother. 2005 Dec;49(12):5172-5
16304197
J Antimicrob Chemother. 2004 Jul;54(1):144-54
15190031
J Antibiot (Tokyo). 2006 Apr;59(4):220-8
16830889
Infect Control Hosp Epidemiol. 2000 Aug;21(8):510-5
10968716
Clin Infect Dis. 2005 Sep 15;41(6):848-54
16107985
Clin Microbiol Infect. 2005 Dec;11(12):974-84
16307551
Ann Med. 2003;35(4):226-34
12846264
Crit Care Med. 1999 May;27(5):887-92
10362409
Diagn Microbiol Infect Dis. 2007 Dec;59(4):467-72
17997070
Curr Opin Investig Drugs. 2002 Feb;3(2):218-24
12020049
J Clin Microbiol. 2006 Sep;44(9):3318-24
16954267
J Antimicrob Chemother. 2005 Jun;55(6):944-9
15872043